Prelude Therapeutics (PRLD) paused both clinical SMARCA2 degraders in November 2025 and pivoted to a JAK2V617F program optioned by Incyte. The Q1 2026 10-Q filed May 12 closed two open questions: liquidity is resolved, and there is now a second clinical asset — the only public KAT6A degrader globally.

What the filing says

Liquidity resolved. Cash $84.8M at March 31, plus $85.5M net from an April equity offering at $4.44 (Goldman/Evercore). Pro-forma ≈$170M. Management states funds sufficient "at least the next twelve months from the filing date." No going concern. Q1 net loss $10.4M (-68% YoY); run-rate burn ≈$13-14M/quarter, with $4.5-5M/quarter Incyte deferred revenue through ~Q1 2027.

JAK2 Phase 1 commenced. PRT12396 began enrollment in polycythemia vera and myelofibrosis, hitting the Q2 2026 guidance from the February IND clearance.

KAT6A degrader emerged. PRT13722, a selective KAT6A targeted-protein-degrader for HR+/HER2- breast cancer. Preclinical data presented at AACR April 20, 2026. IND filing on track for mid-2026, Phase 1 H2 2026.

What the market thinks

Four analysts cover PRLD; mean target $6.88 (+55%). No listed options. Stock at offering price; volume dead (0.5M today vs 1.2x average). Street model centers on JAK2-Incyte option economics. KAT6A does not appear in any published DCF.

Why the gap exists

Three reasons.

First, information lag. AACR poster is 25 days old. Small-cap biotech with four analysts updates slowly.

Second, cross-ticker synthesis required. Pfizer prifetrastat (PF-07248144) Phase 3 KATSIS-1 showed 38.5% Grade 3+ neutropenia in Phase 1 — on-target effect of KAT6 catalytic inhibition. Olema OP-3136 (Phase 1, ASCO May 30) and Menarini MEN2312 (Phase 1) are also inhibitors. PRLD is the only public KAT6A degrader globally; the AACR poster claims preclinical hematological safety advantage vs the inhibitor class. The differentiation thesis: degrader bypasses inhibitor-class neutropenia, enables CDK4/6i combinations the inhibitor class cannot tolerate. Cross-ticker class-effect arguments are sell-side blind spots.

Third, platform credibility scar. PRLD's own SMARCA2 degraders failed Phase 1 in late 2025. Discounting this platform is reasonable, not biased.

Specialist money has marked the gap: OrbiMed and Bonita Capital combined for $25M in the April $4.44 offering. They are not modeling +55%.

Risks, ranked

1. PFE KATSIS-1 reads clean on safety. Prifetrastat Gr3+ neutropenia substantially below 38.5%, or manageable in CDK4/6i combination → PRLD's degrader differentiation collapses to me-too preclinical asset on a Pfizer-validated target. Likely timeline 2027-2028.
2. Preclinical-to-clinical translation gap. PRLD's SMARCA2 degraders died in Phase 1. Safety claim may not survive contact with patients. First testable late 2027.
3. JAK2 Phase 1 safety/PK issue. Incyte walks; $100M+ option exercise vanishes.
4. XBI sector beta. Roughly 40% of variance is sector tide. Rate scares dominate idio thesis in those regimes.
5. Crowded KAT6 landscape. Three clinical inhibitors plus private programs. Even with degrader differentiation, the addressable market in HR+/HER2- breast cancer narrows with each competitor advance.

Catalysts

What would change our mind

• OLMA OP-3136 ASCO shows Gr3+ neutropenia <25% with manageable dose intensity — weakens the class-effect wall thesis materially.
• Pfizer KATSIS-1 reports positive safety signal or expansion to additional indications — validates target while killing PRLD differentiation.
• PRT12396 Phase 1 cohort 1 reports hematological toxicity or non-engagement of JAK2V617F.
• New public competitor announces a KAT6A degrader program — erodes monopoly framing.
• OrbiMed or Bonita 13G filing shows position reduction post-offering — specialist money walking is a strong negative signal.

Evidence

Memo LR: 1.5 (bullish — market underweighting KAT6A as second asset; cross-ticker class-effect synthesis adds novelty over consensus; not extreme given execution risk on multiple legs and ≈40% sector beta dilution of clean idio exposure)